ArticleHepatobiliary surgery and nutrition2025

Empagliflozin for non-diabetic metabolic dysfunction-associated steatotic liver disease: a promising therapeutic agent in transition.

Mohamed El-Kassas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.